Subcutaneous pharmacokinetics of ceftazidime in buffalo calves

被引:1
作者
Ul Haq, Shah Ahsan [1 ]
Sharma, S. K. [1 ]
机构
[1] Guru Angad Dev Vet & Anim Sci Univ, Dept Pharmacol & Toxicol, Ludhiana 141004, Punjab, India
关键词
Buffalo Calves; Ceftazidime; Pharmacokinetics; Urinary excretion; ANTIBIOTICS; INDIVIDUALIZATION; SUSCEPTIBILITY; CEFTRIAXONE; TISSUE; MODEL; DOGS;
D O I
暂无
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
The pharmacokinetics and urinary excretion of ceftazidime, a third generation cephalosporin, was investigated in buffalo calves (6) following a single subcutaneous administration (10 mg/kg). Ceftazidime concentrations in plasma and urine were estimated by microbiological assay technique using Escherichia coli as test organism. Pharmacokinetic analysis of disposition data indicated that subcutaneous administration data were best described by I-compartment open model. The peak plasma levels of ceftazidime were 24.1 +/- 0.26 mu g/ml at 45 min and the drug was detected upto 14 h. The absorption half-life and elimination half-life were 0.38 +/- 0.07 h and 3.32 +/- 0.23 h, respectively. The apparent volume of distribution and total body clearance were 0.18 +/- 0.01 L/kg and 39.2 +/- 1.22 ml/kg/h, respectively. The urinary excretion of ceftazidime in 36 h, was 29.9 +/- 5.34% of total administrated dose. An efficacy predictor, measured as the time over which the active drug exceeds the bacterial minimum inhibitory concentration (T > MIC), was calculated. T > MIC was in the range 91-137% of the recommended dosing interval (8-12 h) after subcutaneous administration, for bacteria with a MIC90 <= 25 mu g/ml.
引用
收藏
页码:569 / 572
页数:4
相关论文
共 24 条
[11]  
Klein NC, 1995, ADV THER, V17, P83
[12]   COMPARATIVE PHARMACOKINETICS OF YM-13115, CEFTRIAXONE, AND CEFTAZIDIME IN RATS, DOGS, AND RHESUS-MONKEYS [J].
MATSUI, H ;
KOMIYA, M ;
IKEDA, C ;
TACHIBANA, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (02) :204-207
[13]  
Meibohm B, 1997, INT J CLIN PHARM TH, V35, P401
[14]   Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa [J].
Moore, KW ;
Trepanier, LA ;
Lautzenhiser, SJ ;
Fialkowski, JP ;
Rosin, E .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2000, 61 (10) :1204-1208
[15]   Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres [J].
Rhomberg, PR ;
Jones, RN ;
Sader, HS .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (01) :52-59
[16]   PHARMACOKINETICS OF CEFTAZIDIME IN SHEEP AND ITS PENETRATION INTO TISSUE AND PERITONEAL FLUIDS [J].
RULE, R ;
PERELLI, MC .
RESEARCH IN VETERINARY SCIENCE, 1991, 51 (03) :233-238
[17]   The pharmacokinetics of ceftazidime in lactating and non-lactating cows [J].
Rule, R ;
Quiroga, GH ;
Rubio, M ;
Buschiazzo, HO ;
Buschiazzo, PM .
VETERINARY RESEARCH COMMUNICATIONS, 1996, 20 (06) :543-550
[18]   PHARMACOKINETICS AND THERAPEUTIC EFFICACY OF IMIPENEM, CEFTAZIDIME, AND CEFTRIAXONE IN EXPERIMENTAL MENINGITIS DUE TO AN AMPICILLIN-RESISTANT AND CHLORAMPHENICOL-RESISTANT STRAIN OF HEMOPHILUS-INFLUENZAE TYPE-B [J].
SAKATA, Y ;
MCCRACKEN, GH ;
THOMAS, ML ;
OLSEN, KD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (01) :29-32
[19]  
Sánchez-Navarro A, 1999, CLIN PHARMACOKINET, V37, P289
[20]   MATHEMATICAL EXAMINATION OF DUAL INDIVIDUALIZATION PRINCIPLES (I) - RELATIONSHIPS BETWEEN AUC ABOVE MIC AND AREA UNDER THE INHIBITORY CURVE FOR CEFMENOXIME, CIPROFLOXACIN, AND TOBRAMYCIN [J].
SCHENTAG, JJ ;
NIX, DE ;
ADELMAN, MH .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (10) :1050-1057